Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
|ClinicalTrials.gov Identifier: NCT00478465|
Recruitment Status : Unknown
Verified August 2007 by Stanford University.
Recruitment status was: Active, not recruiting
First Posted : May 24, 2007
Last Update Posted : August 31, 2007
The purpose of this study determine whether the drug valganciclovir has a significant and real benefit on the central core of symptoms experienced by patients who have high titers to EBV and HHV-6 and are experiencing long-standing fatigue and cognitive impairment (CFS).
In addition, to characterize a quantifiable biological marker in these patients that will facilitate the identification of those likely to respond to valganciclovir and will make it possible to assess response to treatment.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Fatigue Syndrome||Drug: valganciclovir||Phase 1 Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Valganciclovir (Valcyte) in Patients Experiencing Chronic Fatigue Syndrome With Elevated Antibody Titers Against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV)|
|Study Start Date :||May 2007|
|Estimated Study Completion Date :||August 2007|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00478465
|United States, California|
|Stanford University Medical Center|
|Stanford, California, United States, 94305|
|Principal Investigator:||Jose G Montoya, MD||Stanford University|